Pharmaceutical compound
| Clinical data | |
|---|---|
| Other names | McN-5707 |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C18H18ClN |
| Molar mass | 283.80 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Mcn 5707 is a SNDRI agent designated for the treatment of depression. It was developed by Bruce Maryanoff of McNeil (now Johnson & Johnson) in the 1980s.[1][2]
Ki digits
[edit]These are the Ki digits:
| Compound 24b | DA | NE | SER |
|---|---|---|---|
| racemic | 35.9 | 1.9 | 8.5 |
| (+) | 17.5 | 1.1 | 5.5 |
| (-) | 775 | 261 | 537 |
As can be seen most of the Ki activity resides in a single optical antipode (or enantiomer). Hence, there is a good eudysmic ratio
SAR
[edit]For related agents, see: JNJ-7925476, McN-4612, McN-5292, McN-5558, McN5652 & McN-5908.
Other examples of ortho-chloro-phenyl rings include:
References
[edit]- ^ Maryanoff BE, Shank RP, Gardocki JF (1986). "McN-5707 and McN-5652-Z". Drugs of the Future. 11 (1): 18. doi:10.1358/dof.1986.011.01.51629.
- ^ Maryanoff BE, McComsey DF, Castanzo MJ, Setler PE, Gardocki JF, Shank RP, et al. (August 1984). "Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin". Journal of Medicinal Chemistry. 27 (8): 943–6. doi:10.1021/jm00374a001. PMID 6747993.
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||